Nikkei Edges Lower as Traders Brace for Nvidia Earnings

MT NewswiresNov 20 01:47 ET

MediPal Holdings Merges Subsidiaries to Streamline Sales Network, Medical Equipment Business

MT NewswiresNov 19 18:59 ET

Chordia Research Memo (1): Advancing the development of potential blockbuster anticancer drugs by a biotech venture that may become a block inc.

Chordia Therapeutics <190A> was founded by drug discovery researchers spun out from takeda pharmaceuticals sp adr <4502>, specializing in the development of small molecule anticancer drugs. The core business ranges from exploratory research to clinical research, with in-house manufacturing and sales through partnership strategies domestically, aiming for early profitability by licensing out overseas. Listed on the Tokyo Stock Exchange Growth Market in June 2024.

Fisco JapanNov 18 23:01 ET

Medipal Holdings: Confirmation letter

EDINETNov 12 19:56 ET · Announcements

Medipal Holdings: Semi-Annual Report - 116th Term (2024/04/01 - 2025/03/31)

EDINETNov 12 19:54 ET · Announcements

Sumitomo Electric, Mabuchi, etc. (Additional) Rating

Upgrade - Bullish Code Stock Name Securities Company Previous After Change ---------------------------------- <6080> M&A Capcom Maclory "Under P" "Out P" <6752> Panasonic HD Maclory "Neutral" "Out P" Target Stock Price Change Code Stock Name Securities Company Previous After Change ----------------------------------

Fisco JapanNov 4 22:16 ET